Article

Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial

2022-09-21

Abstract excerpt

<h4>BACKGROUND</h4> Over 20% of cases and 0.4% of deaths from Covid-19 occur in children. Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein vaccine NVX-CoV2373 in adults, the PREVENT-19 trial enrolled adolescents. <h4>METHODS</h4> Safety, immunogenicity, and efficacy of NVX-CoV2373 were evaluated in adolescents aged 12 to <18 years in an expansion of PREVENT-19, a phase 3,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: beb3fec2-4736-51b9-be24-35f2bec516d0
DOI: 10.1101/2022.09.20.22279903

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialDOI 10.1101/2022.09.20.22279903Read

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)Semantic proximity Read

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoSemantic proximity Read

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity Read

NVX-CoV2373 Vaccine Efficacy Against Hospitalization: A<i>post hoc</i>analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trialSemantic proximity Read

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantSemantic proximity Read

Effectiveness of Mrna Booster Vaccination Against Mild and Severe COVID-19 During Delta and Omicron Variant Circulation in Germany: An Analysis of National Surveillance DataSemantic proximity Read

Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adultsSemantic proximity Read

Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, EnglandSemantic proximity Read

Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Safety and effectiveness of COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in SwedenSemantic proximity Read

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsSemantic proximity Read